SavedAdd your journal

Journals / Retina-Vitreus / 2016 / Cilt: 24 - Sayı: 3

Short Term Clinical Outcomes For Intravitreal Dexamethasone Implant in Retinal Vein Occlusion Patients

Retina Ven Tıkanıklığı Olgularında Vitre İçi Deksametazon İmplantının Kısa Dönem Sonuçları*

Samet GÜLKAŞ
ÖZLEM NACİYE ATAN ŞAHİN
Pages
227–231
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Moreover, it is a safer treatment alternative than triamcinolone for side effect of steroids.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate short term results of intravitreal dexamethasone implant for macular edema due to retinal branch vein occlusion (BRVO) and central vein occlusion(CRVO).Material and Methods: 31 eyes of 31 patients (15 male,16 female, mean age:59.7) with either BRVO or CRVO were assessed during 6 months prospectively .Treatment naive patients who had <20/50 (Snellen Chart) of visual acuity with >=250 µm of central macular edema (CME) were enrolled.
📊
Key Findings & Data:During follow-up, all subjects received 0.7 mg intravitreal injection once.At each visit (preop.,1-3 and 6 months later) subjects were evaluated with best corrected visual acuity (BCVA,logMAR), central macular thickness (CMT, optical coherence tomography), slit-lamp examination and intraocular pressure.
💡
Conclusion & Impact:Moreover, it is a safer treatment alternative than triamcinolone for side effect of steroids.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate short term results of intravitreal dexamethasone implant for macular edema due to retinal branch vein occlusion (BRVO) and central vein occlusion(CRVO).Material and Methods: 31 eyes of 31 patients (15 male,16 female, mean age:59.7) with either BRVO or CRVO were assessed during 6 months prospectively .Treatment naive patients who had <20/50 (Snellen Chart) of visual acuity with >=250 µm of central macular edema (CME) were enrolled. During follow-up, all subjects received 0.7 mg intravitreal injection once.At each visit (preop.,1-3 and 6 months later) subjects were evaluated with best corrected visual acuity (BCVA,logMAR), central macular thickness (CMT, optical coherence tomography), slit-lamp examination and intraocular pressure. Lens opacities were assessed according to lens opacities classification III (LOCSIII) Results: BCVA (logMAR) improved with mean difference score of 0.12 (p<0.01) and 0.05 (p>0.05) at 3rd and 6th month visits, respectively in CRVO subjects. CMT (µm) decreased with mean difference of 177.75 µm (p<0.05) and 10.75µm (p>0.05) at 3rd and 6th month visits, respectively in CRVO subjects. BCVA (logMAR) improved with mean difference score of 0.17 (p<0.01) and 0.22 (p<0.05) at 3rd and 6th month visits, respectively in BRVO subjects.CMT (µm) decreased with mean difference value of 130 µm (p<0.05) and 51.75 µm (p>0.05) at 3rd and 6th month visits, respectively in BRVO subjects. 3 of 31 eyes which had high IOP (>=21 mmHg) were controlled with medical treatment. 8 of 31 cases had mild cataract and none need cataract surgery. Conclusions: Intravitreal dexamethasone implant can be considered as long term effective choice for CME with BRVO and CRVO compared to intravitreal anti-VEGF treatment. Moreover, it is a safer treatment alternative than triamcinolone for side effect of steroids.

Özet

Amaç: Maküler ödemi olan retinal ven dal tıkanıklığı (RVDT) ve santral retinal ven tıkanıklığı (SRVT) olgularında intravitreal deksametazon implantının kısa dönem etkinliğini ve güvenilirliğini değerlendirmek.Gereç ve Yöntem: RVDT ve SRVT'ye bağlı görme kaybı bununla birlikte eşlik eden maküler ödemi olan 31 hastanın 31 gözü (15 erkek, 16 kadın,yaş ortalaması: 59.7) çalışmaya dahil edilerek 6 ay boyunca prospektif olarak değerlendirildi. Tedavi naif, görme keskinliği =250 µm santral maküler kalınlığı (SMÖ) olan hastalara 1 kez 0.7mg intravitreal deksametazon implantı uygulanmıştır. Tedavi öncesi ve sonrası 1.2.3. ve 6.ay takiplerde en iyi düzeltilmiş görme keskinlikleri (EİDGK,Snellen eşeli), santral maküla kalınlıkları (SMK,optik koherans tomografi ), ve göz içi basınçları (GİB, applanasyon tonometri) kontrol edilmiştir. Takiplerde, hastaların slit-lamp biyomikroskopi ile lens opasite dereceleri lens opacities classification III (LOCSIII)' e göre not edilmiştir. Bulgular: SRVT olgularında tedavi öncesi ve sonrası 3. ve 6. ayda EİDGK'leri ortalama farkı (logMAR) sırasıyla 0.12 (p 0.05) olarak, SMK ortalama farkı (µm) ise 177.75 µm (p 0.05) olarak bulunmuştur. VDT olgularında tedavi öncesi ve sonrası 3. ay ve 6.ayda EİDGK'leri ortalama farkı (logMAR) sırasıyla 0.17 (p 0.05) olarak bulunmuştur. Takip süresince 3 hastada GİB>=21 mmHg saptanmıştır. Lens opasiteleri LOCS III' e göre tedavi öncesi ile karşılaştırıldığında 8 olguda hafif derecede katarakt progresyonu saptanmış, cerrahi gerektirecek progresyon saptanmamıştır. Sonuç: İntravitreal deksametazon implantı, VDT ve SRVT'ye bağlı maküler ödem tedavisinde anti-VEGF ajanlara göre daha uzun sure etkili bir uygulama olup, bunun yanısıra steoridlerin yan etkileri dikkate alındığında triamsinolona oranla daha güvenilir bir tedavi yöntemidir.

🔖

Cite This Article

GÜLKAŞ, S., ŞAHİN, Ö. N. A. (2016). Short Term Clinical Outcomes For Intravitreal Dexamethasone Implant in Retinal Vein Occlusion Patients. Retina-Vitreus, Cilt: 24 - Sayı: 3, 227–231. https://ajindex.com/articles/304965

References (13)

  1. Hayreh SS., Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic charac- teristics, Am J Ophthalmol. 1994;117:429-41.
  2. R Klein, B E Klein, S E Moss et al. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study, Trans Am Ophthalmol Soc. 2000;98:133-43.
  3. McIntosh RL, Rogers SL, Lim L et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;117:1113-23.
  4. Rogers SL, McIntosh RL, Lim L et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;1171094-101.
  5. Campochiaro PA, Hafiz G, Shah SM et al. Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Cri- tical Stimulator. Molecular Therapy. 2008;16:791-9.
  6. Brown, D.M., Campochiaro, P.A., Singh, R.P. and CRUISE Investi- gators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124-33.
  7. Algvere PV, Epstein D, von Wendt G et al. Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. European Journal of Ophthalmology. 2011;21:789-95.
  8. Prager F, Michels S, Kriechbaum K, Georgopoulos M et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthal- mol. 2009;93:452-6.
  9. Patel PJ, Zaheer I, Karia N. Intravitreal triamcinolone acetonide for ma- cular oedema owing to retinal vein occlusion. Eye (Lond). 2008;22:60-4.
  10. Chan A, Leung LS, Blumenkranz MS. Critical appraisal of the clini- cal utility of the dexamethasone intravitreal implant (Ozurdex) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion. Clin Ophthalmol. 2011;5:1043-9. Royal College of Ophthalmologists. Retinal vein occlusion (RVO) inte- rim guidelines.http://www.rcophth.ac.uk/docs/publications/published- guidelines/RVO_Guidelines_Feb_2009.pdf; February 2009.
  11. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snel- len visual acuity measurements. Retina2010; Jul-Aug; 30:1046-50.
  12. L. T. Chylack Jr., J. K. Wolfe, D. M. Singer et al. Longitudinal Study of Cataract Study Group. The lens opacities classification system III. Archives of Ophthalmology. 1993;111: 831-6.
  13. Haller, J., Bandello, F., Belfort, R. Jr et al. OZURDEX GENEVA Study Gr